We are pleased and honored to introduce Bia Labate, PhD, to the Soltara advisory team as Science and Culture Coordinator.
08:43 min
CLEAR ALL
Dr Robin Carhart-Harris talks about his scientific research into the effects and potential therapeutic uses of psychedelic drugs. Join him as he discusses brain imaging work involving psilocybin, the active ingredient of magic mushrooms, and explains how the drug works in the brain.
1
New research using psychedelic drugs to understand the brain could lead to new treatments for mental disorders such as depression.
The talk will review brain imaging work on the action of psychedelics on the brain and describe the results of a clinical trial assessing psilocybin as a treatment for depression. It will also review the broader societal impact of psychedelic drug-use and discuss its implications.
Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization.
Dr. Robin Carhart-Harris, of the Neuropsychopharmacology Unit, Imperial College London, discusses research on Psilocybin and how psychedelics could be used in therapy to help with depression, addiction, and other problems of rigid thought patterns.
Robin has been conducting pioneering brain imaging studies of psychedelic drugs. Most recently, he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression, and his talk looks at how these drugs can be used in treatment.
Psychedelics afford a unique opportunity to expand our understanding of consciousness and its altered states, to develop techniques for enhancing consciousness, and to uncover new avenues of treatment and improved therapeutic techniques.